SyMAP — AI Tools for Pharmaceutical Pricing

What is SyMAP?

SyMAP is a modular platform of AI‑powered applications built specifically for pharmaceutical pricing and market access teams. Our suite brings together explainable AI, robust simulation engines, and enterprise governance to answer high‑stakes pricing questions. From SyMAP IRP for International Reference Pricing to SyMAP GENEROUS for Medicaid MFN modelling and the upcoming SyMAP MFN for comprehensive Most Favored Nation analysis—each module combines transparent calculations with AI that explains the why behind every result.

From Spreadsheets to Strategy

Replace fragmented Excel models with a purpose-built platform for IRP and MFN pricing analysis.

Scenario Power, Simple Interface

Multi-year modelling, sensitivity analysis, and what-if testing in an intuitive, modern UI.

Explainable AI

Interprets results in plain language, highlights risks and opportunities, and recommends strategic next steps.

SyMAP GENEROUS — Product summary dashboard

SyMAP IRP — International Reference Pricing

SyMAP Tools

Coming Soon

SyMAP IRP — International Reference Pricing with AI

SyMAP IRP combines rigorous, transparent IRP modelling with an AI engine that interprets results, highlights risks and opportunities, and recommends next steps. It captures country rules, price types, FX and timing precisely—then turns outputs into defendable strategy and action.

Rigorous IRP Modelling

Accurate country rules, baskets, and price-type logic
Multi-year projections with launch timing and review cycle logic
Transparent calculations available for audit and documentation

Powerful Simulation Tools

What-if analysis across price points, launch sequences, and pricing thresholds
Compare multiple scenarios with visual dashboards
Exportable results for reporting and stakeholder alignment

AI-Powered Insights

Interprets results and explains key drivers in plain language
Highlights risks and opportunities across markets
Admin controls for AI permissions, data access, and feature toggles

SyMAP IRP — International Reference Pricing platform interface

Key Use Cases

Launch Sequence Optimisation

Model launch orders to minimise IRP erosion and maximise revenue.

In-Market Price Changes

Simulate adjustments and understand cascading effects across baskets.

Loss of Exclusivity

Model pricing impacts when key reference countries face generic entry.

Strategic Planning

Multi-year projections for forecasting and lifecycle management.

Book a demo

SyMAP GENEROUS — CMS GENEROUS Model Simulation & Medicaid MFN Pricing Tool

SyMAP GENEROUS is our AI-powered tool for the CMS GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid)—the voluntary federal demonstration program bringing Most Favored Nation (MFN) pricing to Medicaid from 2026–2030. Model MFN benchmark prices, calculate supplemental rebates, and analyse the financial impact of GENEROUS participation across your drug portfolio.

MFN Benchmark Price Modelling

Calculate MFN prices using international reference pricing from 8 countries
Compare MFN benchmark against current Medicaid net prices and AMP
Model Guaranteed Net Unit Price (GNUP) under the GENEROUS program

Medicaid Rebate & Revenue Analysis

Calculate basic, inflationary, and GENEROUS supplemental rebates
Model revenue impact: standard Medicaid rebate vs MFN-based pricing
Project 5-year cumulative rebate obligations (2026–2030)

GENEROUS Strategic Decision Support

Portfolio-level analysis across multiple drugs and NDCs
Scenario planning for international price changes affecting MFN benchmarks
AI-driven interpretation of GENEROUS Model results and recommendations

SyMAP GENEROUS — CMS GENEROUS Model setup configuration for Medicaid MFN drug pricing simulation

SyMAP GENEROUS — MFN pricing results timeline showing Medicaid rebate projections 2026-2030

SyMAP GENEROUS — Product summary dashboard for GENEROUS Model portfolio analysis and MFN impact

SyMAP GENEROUS — MFN benchmark price table comparing international reference prices and Medicaid net prices

SyMAP GENEROUS — Portfolio-level GENEROUS Model analysis showing MFN drug pricing impact across products

SyMAP GENEROUS — International reference prices for MFN benchmark calculation under CMS GENEROUS Model

GENEROUS Model Use Cases

GENEROUS Participation Decision

Compare GENEROUS MFN pricing against standard Medicaid rebates across your portfolio.

MFN Revenue Impact Analysis

Project cumulative revenue and rebate differences across the 5-year GENEROUS program.

International Pricing & MFN Strategy

Understand how ex-US reference prices flow through to MFN benchmarks and US Medicaid pricing.

GENEROUS Scenario Planning

Test participation periods, FX and PPP assumptions, and international price changes on MFN outcomes.

Understanding the CMS GENEROUS Model & MFN Pricing

The GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid) is a voluntary CMS Innovation Center demonstration program running 2026–2030 that introduces Most Favored Nation (MFN) pricing to Medicaid. Under GENEROUS, participating manufacturers provide supplemental rebates to participating states to align Medicaid net prices with international benchmarks—calculated as the second lowest PPP-adjusted net price across 8 reference countries: Canada, Germany, France, UK, Japan, Italy, Switzerland, and Denmark.

How the MFN Benchmark is Calculated

For each covered outpatient drug (COD), manufacturers report their average net price over the previous 12 months for each of the 8 reference countries—after all rebates, discounts, and price concessions are deducted. CMS then applies a GDP purchasing power parity (PPP) adjustment and uses the second lowest country-specific price as the MFN benchmark.

The Supplemental Rebate Formula

The supplemental rebate is calculated as: WAC – (GNUP + URA), where WAC is the Wholesale Acquisition Cost, GNUP is the Guaranteed Net Unit Price (reflecting the MFN benchmark), and URA is the existing Medicaid Unit Rebate Amount (basic + inflationary rebates). This supplemental rebate is paid quarterly by manufacturers to participating states.

Key Dates & Timeline

Nov 2025 – Mar 31, 2026: Manufacturer applications
Jun 30, 2026: Manufacturer participation agreements signed (rebates retroactive to Jan 1, 2026)
Aug 31, 2026: State sign-up deadline
Dec 31, 2030: Model ends

Participation Requirements

Manufacturers must participate in the Medicaid Drug Rebate Program (MDRP) and agree to provide MFN pricing for all their single source and innovator multiple source CODs. States that accept MFN pricing for a drug agree to adopt standardised coverage criteria negotiated between CMS and the manufacturer, and cannot seek additional supplemental rebates on that drug.

CMS GENEROUS Model
Manufacturer RFA (PDF)

Book a SyMAP GENEROUS Demo

SyMAP MFN — Comprehensive Most Favored Nation Drug Pricing Analysis

Coming Soon

SyMAP MFN will be our dedicated platform for comprehensive Most Favored Nation (MFN) drug pricing analysis beyond the GENEROUS Model. As MFN pricing policies evolve across Medicare, Medicaid, and potential future federal programs, SyMAP MFN will provide pharmaceutical teams with the tools to model, analyse, and strategically respond to MFN-based pricing requirements across all US government payers.

Cross-Program MFN Modelling

Model MFN pricing across Medicare Part B, Part D, and Medicaid
Analyse MFN benchmark methodologies across different federal programs
Compare MFN impacts: IRA drug pricing, GENEROUS, and future MFN policies

International Reference Price Analysis

Track ex-US prices across MFN reference country baskets
Model how international pricing decisions affect US MFN benchmarks
Strategic recommendations for global pricing and MFN optimisation

MFN Policy Intelligence

Stay current with evolving MFN drug pricing regulations
Model proposed and final rule changes to MFN methodologies
AI-powered analysis of MFN policy developments and implications

SyMAP MFN Coming 2026

We’re building comprehensive MFN drug pricing tools to help you navigate the evolving landscape of Most Favored Nation pricing policies across US government payers.

Planned MFN Use Cases

Medicare MFN Impact Analysis

Model MFN pricing impacts across Medicare Part B and Part D programs.

Global-to-US MFN Strategy

Optimise international pricing strategy for US MFN benchmark management.

MFN Policy Tracking

Monitor and model evolving MFN regulations and proposed rule changes.

Unified MFN Dashboard

Single view of MFN exposure across all US government payer programs.

Platform Features

Shared capabilities across SyMAP IRP, SyMAP GENEROUS, and SyMAP MFN—built for pharmaceutical pricing and market access teams navigating international reference pricing and MFN drug pricing policies.

AI Assistant

Context‑aware chat that explains IRP rules, MFN calculations, and GENEROUS Model outcomes in plain language.

Simulation Series

Run price-increment sweeps, scenario comparisons, and sensitivity analyses for IRP and MFN pricing at scale.

Data & Governance

Preserve standard fields; optionally whitelist extended fields; export GENEROUS results and MFN rationales.

Enterprise Readiness

JWT auth, roles, email verification, rate limits, payload guards, CSRF middleware.

Integrations

CSV/JSON import, API endpoints for data sync, and export to Excel/CSV for downstream reporting.

Visual Analytics

Interactive charts, tables, and network maps to explore MFN reference relationships and pricing trends.

FAQs

Which countries and price types are supported in SyMAP IRP?: SyMAP IRP is designed to accommodate common IRP baskets globally, with configurable reference rules and price types (e.g., ex-manufacturer, wholesale, net). FX sources and conversions are clearly shown alongside every calculation.
What is the CMS GENEROUS Model and how does SyMAP GENEROUS help?: The GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid) is a CMS demonstration program running 2026–2030 that introduces Most Favored Nation (MFN) pricing to Medicaid. SyMAP GENEROUS simulates the complete GENEROUS methodology—calculating MFN benchmark prices, supplemental rebates, GNUP, and revenue impacts—to help you decide whether to participate and how to optimise your pricing strategy.
What reference countries does SyMAP GENEROUS use for MFN pricing?: SyMAP GENEROUS uses the 8 countries specified in the CMS GENEROUS Model for MFN benchmark calculation: Canada, Switzerland, Germany, Denmark, France, Italy, Japan, and the United Kingdom. These align with the G-7 (excluding USA) plus Denmark and Switzerland.
Can I model partial GENEROUS participation?: Yes. SyMAP GENEROUS includes a participation period slider that lets you select specific years (e.g., 2027–2029) to model scenarios where you join the GENEROUS Model late or withdraw early from MFN pricing obligations.
Can I restrict what the AI is allowed to do?: Yes. Safe AI actions are opt-in and admin-defined. Users must confirm any AI-initiated change and all actions are logged for audit.
How do I bring my data in?: Use CSV/JSON import or connect via API. Standard fields are preserved, and extended fields can be whitelisted where needed.
What is SyMAP MFN and when will it be available?: SyMAP MFN is our upcoming platform for comprehensive Most Favored Nation drug pricing analysis across all US government payer programs—including Medicare Part B, Part D, and Medicaid. While SyMAP GENEROUS focuses specifically on the CMS GENEROUS Model, SyMAP MFN will provide a unified view of MFN exposure and strategy. Expected launch: 2026.
Is this available on‑premise?: Deployment options are flexible. Speak to us about your security requirements and hosting preferences.